Munich-based biotech company HMNC Brain Health, focused on the development of personalised therapies in psychiatry, has received an additional €9 million from its current investors.
The supplemental investment brings the total raised to date to €28 million and will strengthen HMNC’s financial position in advance of an expected Series B round later this year.
The investment, in the form of...
